NASDAQ:ONCS OncoSec Medical - ONCS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding OncoSec Medical Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. $1.70 +0.08 (+4.94%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.64▼$1.7550-Day Range$1.61▼$3.8552-Week Range$1.50▼$31.90Volume111,377 shsAverage Volume144,726 shsMarket Capitalization$5.05 millionP/E RatioN/ADividend YieldN/APrice Target$110.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media OncoSec Medical MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside6,370.6% Upside$110.00 Price TargetShort InterestHealthy2.18% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.65 out of 5 stars 3.0 Analyst's Opinion Consensus RatingOncoSec Medical has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $110.00, OncoSec Medical has a forecasted upside of 6,370.6% from its current price of $1.70.Amount of Analyst CoverageOncoSec Medical has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.18% of the float of OncoSec Medical has been sold short.Short Interest Ratio / Days to CoverOncoSec Medical has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in OncoSec Medical has recently decreased by 2.84%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldOncoSec Medical does not currently pay a dividend.Dividend GrowthOncoSec Medical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ONCS. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 1 people have searched for ONCS on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows2 people have added OncoSec Medical to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OncoSec Medical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.32% of the stock of OncoSec Medical is held by insiders. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of OncoSec Medical is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OncoSec Medical is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncoSec Medical has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About OncoSec Medical (NASDAQ:ONCS) StockOncoSec Medical, Inc. is a biotechnology company focused on designing, developing and commercializing therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, uses an electroporation device, with the aim of reversing the immunosuppressive microenvironment in the treated tumor. The company was founded by Avtar S. Dhillon and Punit S. Dhillon on February 8, 2008 and is headquartered in Pennington, NJ.Read More Receive ONCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OncoSec Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address ONCS Stock News HeadlinesJanuary 16, 2023 | reuters.comONCS.OQ - | Stock Price & Latest News | ReutersJanuary 5, 2023 | benzinga.comOncoSec Medical Stock (NASDAQ:ONCS), Quotes and News SummaryFebruary 5, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...December 8, 2022 | msn.comPeering Into OncoSec Medical's Recent Short InterestDecember 5, 2022 | finance.yahoo.comOncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022November 30, 2022 | marketwatch.comOncoSec Shares Drop 25% on Equity Offer Pricing After 51% Tuesday SurgeNovember 30, 2022 | finance.yahoo.comOncoSec Announces Pricing of $3.5 Million Public OfferingNovember 24, 2022 | finance.yahoo.comOncoSec Touts Encouraging Early Data For Opdivo Combined Immunotherapy For Skin CancerFebruary 5, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...November 23, 2022 | seekingalpha.comOncoSec provides updates on cancer programs in new filingNovember 22, 2022 | msn.comLooking Into OncoSec Medical's Recent Short InterestNovember 15, 2022 | finance.yahoo.comOncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanomaNovember 11, 2022 | finance.yahoo.comOncoSec Announces Positive Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma Refractory to anti-PD-1 TreatmentNovember 8, 2022 | marketwatch.comOncoSec Medical Shares Hit New Depths Ahead of Reverse Stock Split >ONCSNovember 8, 2022 | finance.yahoo.comOncoSec Announces Reverse Stock SplitOctober 13, 2022 | finance.yahoo.comOncoSec Cuts Workforce, Prioritizes PipelineOctober 4, 2022 | marketwatch.comOncoSec Medical to Restructure, Cut JobsOctober 4, 2022 | markets.businessinsider.comOncoSec Medical To Reduce Staff By About 45%October 4, 2022 | finance.yahoo.comOncoSec Announces Pipeline Prioritization and Workforce ReductionApril 29, 2022 | seekingalpha.comRobert Arch joins OncoSec Medical as CEOApril 29, 2022 | finance.yahoo.comOncoSec Appoints Dr. Robert Arch as President and Chief Executive OfficerMarch 16, 2022 | benzinga.comBTIG Maintains Buy on OncoSec Medical, Lowers Price Target to $5February 23, 2022 | seekingalpha.comOncoSec appoints new finance chiefOctober 9, 2021 | nasdaq.comOncoSec Medical Inc Shares Approach 52-Week Low - Market MoverAugust 3, 2021 | finance.yahoo.comOncoSec to Participate in Fireside Chat at BTIG Virtual Biotechnology ConferenceJuly 27, 2021 | nasdaq.comOncoSec Medical Incorporated Common Stock (ONCS)July 7, 2021 | marketwatch.comOncoSec Hikes on Start of Clinical TrialSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ONCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OncoSec Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address ONCS Company Calendar Last Earnings12/15/2022Today2/05/2023Next Earnings (Estimated)3/21/2023Fiscal Year End7/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ONCS CUSIPN/A CIK1444307 Webwww.oncosec.com Phone(855) 662-6732Fax858-430-3832Employees54Year FoundedN/APrice Target and Rating Average Stock Price Forecast$110.00 High Stock Price Forecast$110.00 Low Stock Price Forecast$110.00 Forecasted Upside/Downside+6,370.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($18.1310) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-34,180,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-334.01% Return on Assets-130.51% Debt Debt-to-Equity RatioN/A Current Ratio1.25 Quick Ratio1.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.42 per share Price / Book0.50Miscellaneous Outstanding Shares2,970,000Free Float2,932,000Market Cap$5.05 million OptionableNot Optionable Beta1.65 Key ExecutivesRobert H. ArchPresident, CEO & Non-Independent DirectorGeorge ChiChief Financial OfficerDavid CantonVice President-Research & DevelopmentSandra AungChief Clinical Development Officer & Senior VPBridget O'KeeffeVice President-Clinical DevelopmentKey CompetitorsBenitec BiopharmaNASDAQ:BNTCAvenue TherapeuticsNASDAQ:ATXI180 Life SciencesNASDAQ:ATNFEnveric BiosciencesNASDAQ:ENVBQualigen TherapeuticsNASDAQ:QLGNView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 14,030 shares on 11/15/2022Ownership: 40.016%Renaissance Technologies LLCSold 5,500 shares on 11/14/2022Ownership: 3.759%Robert J DelaversanoSold 283 sharesTotal: $104.71 ($0.37/share)Robert J DelaversanoSold 284 sharesTotal: $201.64 ($0.71/share)Robert J DelaversanoSold 274 sharesTotal: $227.42 ($0.83/share)View All Insider TransactionsView All Institutional Transactions ONCS Stock - Frequently Asked Questions Should I buy or sell OncoSec Medical stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OncoSec Medical in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ONCS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ONCS, but not buy additional shares or sell existing shares. View ONCS analyst ratings or view top-rated stocks. What is OncoSec Medical's stock price forecast for 2023? 1 analysts have issued 12 month price targets for OncoSec Medical's shares. Their ONCS share price forecasts range from $110.00 to $110.00. On average, they anticipate the company's stock price to reach $110.00 in the next twelve months. This suggests a possible upside of 6,370.6% from the stock's current price. View analysts price targets for ONCS or view top-rated stocks among Wall Street analysts. How have ONCS shares performed in 2023? OncoSec Medical's stock was trading at $1.68 on January 1st, 2023. Since then, ONCS stock has increased by 1.2% and is now trading at $1.70. View the best growth stocks for 2023 here. When is OncoSec Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023. View our ONCS earnings forecast. How were OncoSec Medical's earnings last quarter? OncoSec Medical Incorporated (NASDAQ:ONCS) issued its earnings results on Thursday, December, 15th. The biotechnology company reported ($4.50) earnings per share for the quarter. When did OncoSec Medical's stock split? OncoSec Medical shares reverse split before market open on Wednesday, November 9th 2022. The 1-22 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is Punit Dhillon's approval rating as OncoSec Medical's CEO? 2 employees have rated OncoSec Medical Chief Executive Officer Punit Dhillon on Glassdoor.com. Punit Dhillon has an approval rating of 50% among the company's employees. This puts Punit Dhillon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of OncoSec Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other OncoSec Medical investors own include Cytokinetics (CYTK), Inovio Pharmaceuticals (INO), XOMA (XOMA), Anavex Life Sciences (AVXL), Walt Disney (DIS), Idera Pharmaceuticals (IDRA), Sorrento Therapeutics (SRNE), Amarin (AMRN), Dynavax Technologies (DVAX) and Trevena (TRVN). What is OncoSec Medical's stock symbol? OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS." Who are OncoSec Medical's major shareholders? OncoSec Medical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alpha Holdings, Inc, Brian A Leuthner, Daniel J O'connor, Grand Pharmaceutical & H China, Robert J Delaversano, Robert J Delaversano and Yuhang Zhao. View institutional ownership trends. How do I buy shares of OncoSec Medical? Shares of ONCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is OncoSec Medical's stock price today? One share of ONCS stock can currently be purchased for approximately $1.70. How much money does OncoSec Medical make? OncoSec Medical (NASDAQ:ONCS) has a market capitalization of $5.05 million. The biotechnology company earns $-34,180,000.00 in net income (profit) each year or ($18.13) on an earnings per share basis. How can I contact OncoSec Medical? OncoSec Medical's mailing address is 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121. The official website for the company is www.oncosec.com. The biotechnology company can be reached via phone at (855) 662-6732, via email at investors@oncosec.com, or via fax at 858-430-3832. This page (NASDAQ:ONCS) was last updated on 2/5/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.